Ye Qin

Dr. Ye Qin


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
LBLei Bao
Lei Bao
PZPing Zhu
Ping Zhu
YMYuan Mou
Yuan Mou
YSYinhong Song
Yinhong Song
YQYe Qin
Ye Qin
Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years. However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms. Notably, inhibition of LSD1 turns “cold tumors” into “hot tumors” and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy.

22 January 2022 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
WYWang Yan
Wang Yan
LWLulu Wang
Lulu Wang
ZCZhaoying Chen
Zhaoying Chen
CGChengyao Gu
Chengyao Gu
CCCaijing Chen
Caijing Chen
YQYe Qin
Ye Qin

9 December 2021 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
LLLingyue Li
Lingyue Li
YWYiyu Wang
Yiyu Wang
YMYuan Mou
Yuan Mou
HWHao Wu
Hao Wu
YQYe Qin
Ye Qin
Background. Lysine-specific demethylase 1A (KDM1A) is a histone demethylation enzyme and a crucial epigenetic factor for multiple pathological pathways that mediate carcinogenesis and immunogenicity. Although increasing evidence supposes the association between KDM1A and cancers, no systematic multi-omics analysis of KDM1A is available. Methods. We systematically evaluated the KDM1A expression of various cancer and normal tissues and the unique relationship between KDM1A expression and prognosis of cancer cases based on The Cancer Genome Atlas (TCGA), Genotype Tissue Expression (GTEx), and Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. The genetic variations, phosphorylation, and DNA methylation of KDM1A were analyzed via various tools. We further analyzed the correlation of KDM1A expression and fibroblasts and immune cell infiltration score of TCGA samples via TIMER2.0. Results. KDM1A was highly expressed in 17 types of total 33 cancers, while it expressed low levels in only 4 cancers. High KDM1A expression was associated with worse survival status in various cancers. KDM1A expression was positively correlated with the cancer-associated fibroblasts and myeloid-derived suppressor cells infiltration levels in most cancer types. Additionally, KDM1A in most cancer types was negatively correlated with Th1 cell infiltration and positively correlated with Th2 cells. Moreover, spliceosome, cell cycle, and RNA transport pathways were involved in the functional mechanisms of KDM1A via enrichment analysis. Conclusions. Our study describes the epigenetic factor KDM1A as an oncogene and prognostic biomarker. Our findings provide valuable guidance for further analysis of KDM1A function in pathogenesis and potential clinical treatment.

1 October 2010 in Enzyme and Microbial Technology
Verified
Journal Article
Closed access
ZLZhimin Li
Zhimin Li
XPXubin Ping
Xubin Ping
YQYe Qin
Ye Qin
XHXiudong Huang
Xiudong Huang
ZCZhifang Cao
Zhifang Cao

30 November 2018 in BMB Reports
Verified
Journal Article
Open access
PDF file
MWMulan Wei
Mulan Wei
XLXujie Liu
Xujie Liu
CCChunyu Cao
Chunyu Cao
JYJianlin Yang
Jianlin Yang
YLYafeng Lv
Yafeng Lv
YQYe Qin
Ye Qin
Mulan Wei, Xujie Liu, Chunyu Cao, Jianlin Yang, Yafeng Lv, Jiaojiao Huang, Yanlin Wang & Ye Qin. BMB Reports 2018;51:572-7. https://doi.org/10.5483/BMBRep.2018.51.11.076

14 June 2024 in Heliyon
Verified
Journal Article
Open access
YWYiyu Wang
Yiyu Wang
MSMeng Sun
Meng Sun
ZHZhong He
Zhong He
YHYing Han
Ying Han
YSYinhong Song
Yinhong Song
ZDZhangshuang Deng
Zhangshuang Deng
Estrogen receptor-positive (ER+) breast cancer seriously endangers the women's physical and mental health worldwide and ER targeting therapy is vital. Here, we found that a citrus polymethoxyflavones (PMFs)-rich hydrolysate (C-H) and its major components (nobiletin and 3-methoxynobiletin) potently degrade ERα protein via the ubiquitin-proteasome pathway, thereby impairing the proliferation of ER+ breast cancer cells. Moreover, our study exhibited that C-H combined with tamoxifen (TAM) inhibited the cell proliferation of ER+ breast cancer in vitro. It was further confirmed that C-H decreased tumor growth of ER+ breast cancer in tumor-bearing 129 mice in vivo and improved the efficacy of tamoxifen. Our study revealed that the citrus PMFs have potential applications as pharmaceutical and healthcare products in breast cancer treatment by targeting ERα protein degradation.